Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Medinet Co's Enterprise Value for the quarter that ended in Mar. 2026 was 円5,116.9 Mil.
Medinet Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-1,092.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medinet Co EV-to-EBIT Related Terms
Medinet Co EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Medinet Co's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:2370 vs VRTX, REGN, MRNA: EV-to-EBIT Comparison
For the Biotechnology subindustry, Medinet Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medinet Co EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medinet Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Medinet Co's EV-to-EBIT falls into.
Medinet Co's current Enterprise Value is 円3,871.6 Mil.
Medinet Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-1,092.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medinet Co (TSE:2370) has a EV-to-EBIT of -3.54 as of Sep. 05, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Medinet Co and its competitors. According to the industry distribution chart, Medinet Co ranks #999999 out of 368 companies in the Biotechnology industry.
Is Medinet Co's EV-to-EBIT too high?
Medinet Co's current EV-to-EBIT is -3.54. Based on the distribution chart, Medinet Co ranks #999999 out of 368 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Medinet Co has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Medinet Co's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medinet Co ranks #999999 out of 368 companies for EV-to-EBIT. This places Medinet Co in the lower half of its industry. The industry median EV-to-EBIT is 15.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.55, based on 368 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Medinet Co and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medinet Co's current EV-to-EBIT is -3.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medinet Co stock overvalued right now?
Based on GuruFocus' analysis, Medinet Co (TSE:2370) is currently considered Possible Value Trap. The stock's GF Value™ is 円42.07, compared to a current price of 円25.00 — trading 40.6% below its estimated fair value. The current EV-to-EBIT is -3.54. Medinet Co's overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Medinet Co (TSE:2370), the current EV-to-EBIT is -3.54 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medinet Co (TSE:2370) Overvalued in 2026?
Based on GuruFocus' analysis, Medinet Co stock appears to be undervalued.
The current stock price of 円25.00 is trading 40.6% below its estimated GF Value™ of 円42.07.
GuruFocus considers Medinet Co to be Possible Value Trap.
Key valuation signals for TSE:2370:
EV-to-EBIT: -3.54
GF Value™: 円42.07 vs. price of 円25.00 (40.6% below fair value)
No single metric tells the full story. See the TSE:2370 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medinet Co Ltd is a Japan-based Contract Development and Manufacturing Organization (CDMO). The company is engaged in the research and development of regenerative medical products, investigational products, and specified cell products. MEDINET is a one-stop regenerative medicine and cell therapy solution provider. It provides value chain solutions including personnel training, facility and equipment design, facility operations and management, preparation of standard operating procedures, logistics network, information system, purchasing and production management, quality management solutions to medical institutions, research institutions, and biopharmaceutical companies.
40GF Score
Get the complete analysis for TSE:2370
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2370 has been successfully added to your 
